ArticleNews reportPHN-05922026-11-02 08:05 CT
WSU researcher works to advance peptide-based male contraceptive toward human trials
Source · WSU Insider
TLDR
Washington State University researcher Jon Oatley received a $274,849 Washington Research Foundation grant to advance Alphatide, a peptide-based male contraceptive, toward human trials. The two-year grant will fund final preclinical studies needed to seek FDA permission for human testing; Oatley reported reversible contraceptive effects in mice.
01—Key points
- 01Alphatide targets the interaction between ARRDC5 and TEX38, proteins the researchers identified as essential for sperm development.
- 02Funded studies will examine the peptide’s distribution, duration of activity, and clearance from the body.
- 03Oatley reported no apparent adverse health effects in mouse studies; human testing has not yet begun.
Why it matters Editorial
The research could expand peptide applications to male contraception, but safety and effectiveness in humans remain untested.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.